User profiles for "author:Hai Tran"

Hai Nguyen Tran

Deputy Director: IFAS, Duy Tan University; A/Editor: Water Science and Technology; …
Verified email at duytan.edu.vn
Cited by 9559

Mistakes and inconsistencies regarding adsorption of contaminants from aqueous solutions: a critical review

HN Tran, SJ You, A Hosseini-Bandegharaei, HP Chao - Water research, 2017 - Elsevier
In recent years, adsorption science and technology for water and wastewater treatment has
attracted substantial attention from the scientific community. However, the number of …

Recent progress in the preparation, properties and applications of superhydrophobic nano-based coatings and surfaces: A review

P Nguyen-Tri, HN Tran, CO Plamondon… - Progress in organic …, 2019 - Elsevier
With the recent progress in nanotechnology and material engineering, nano-based coatings
have become multifunctional, smarter, efficient, versatile and durable. Superhydrophobic …

SARS-CoV-2 coronavirus in water and wastewater: A critical review about presence and concern

HN Tran, GT Le, DT Nguyen, RS Juang… - Environmental …, 2021 - Elsevier
The presence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in water
and wastewater has recently been reported. According to the updated literature, the stools …

TRIBUTE: A phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non–small-cell lung cancer

RS Herbst, D Prager, R Hermann… - Journal of clinical …, 2005 - ascopubs.org
Purpose Erlotinib is a potent reversible HER1/epidermal growth factor receptor (EGFR)
tyrosine kinase inhibitor with single-agent activity in patients with non–small-cell lung cancer …

The BATTLE trial: personalizing therapy for lung cancer

ES Kim, RS Herbst, II Wistuba, JJ Lee… - Cancer discovery, 2011 - AACR
Abstract The Biomarker-integrated Approaches of Targeted Therapy for Lung Cancer
Elimination (BATTLE) trial represents the first completed prospective, biopsy-mandated …

Neoadjuvant nivolumab or nivolumab plus ipilimumab in operable non-small cell lung cancer: the phase 2 randomized NEOSTAR trial

T Cascone, WN William Jr, A Weissferdt, CH Leung… - Nature medicine, 2021 - nature.com
Ipilimumab improves clinical outcomes when combined with nivolumab in metastatic non-
small cell lung cancer (NSCLC), but its efficacy and impact on the immune …

An epithelial–mesenchymal transition gene signature predicts resistance to EGFR and PI3K inhibitors and identifies Axl as a therapeutic target for overcoming EGFR …

LA Byers, L Diao, J Wang, P Saintigny, L Girard… - Clinical cancer …, 2013 - AACR
Purpose: Epithelial–mesenchymal transition (EMT) has been associated with metastatic
spread and EGF receptor (EGFR) inhibitor resistance. We developed and validated a robust …

Thermodynamic parameters of cadmium adsorption onto orange peel calculated from various methods: A comparison study

HN Tran, SJ You, HP Chao - Journal of Environmental Chemical …, 2016 - Elsevier
Thermodynamic adsorption investigation plays a key role in estimating adsorptive
mechanisms (ie, physical or chemical). Accuracy estimation of the thermodynamic …

[HTML][HTML] Structure-based classification predicts drug response in EGFR-mutant NSCLC

JP Robichaux, X Le, RSK Vijayan, JK Hicks, S Heeke… - Nature, 2021 - nature.com
Epidermal growth factor receptor (EGFR) mutations typically occur in exons 18–21 and are
established driver mutations in non-small cell lung cancer (NSCLC),–. Targeted therapies …

Phase I/II trial evaluating the anti-vascular endothelial growth factor monoclonal antibody bevacizumab in combination with the HER-1/epidermal growth factor …

RS Herbst, DH Johnson, E Mininberg… - Journal of Clinical …, 2005 - ascopubs.org
Purpose Bevacizumab (Avastin; Genentech, South San Francisco, CA) is a recombinant,
humanized anti-vascular endothelial growth factor monoclonal antibody. Erlotinib HCl …